Sridhar G. Prasad
Independent DirectorDr. Sridhar G. Prasad, Ph.D., is Independent Director of Drugs Made In America Acquisition II Corp. from September 24, 2025. He is Independent Director of Drugs Made In America Acquisition Corp. since January 2025. Dr. Prasad is Founder and serves as Chief Scientific Officer at CalAsia Pharmaceuticals, Inc. Dr. Prasad serves as Chief Scientific Officer at Spectrum Antimicrobials, Inc. Dr. Prasad has been a member of drug discovery teams that discovered multiple drug candidates advanced to various stages of preclinical and clinical development, including Merck’s MK-4965. Dr. Prasad co-founded Plex Pharmaceuticals in 2009, which was acquired by Collidion, Inc. in 2017 and served as its Chief Scientific Officer from 2009 to 2022. He was the lead crystallographer and core member of the team that discovered Alogliptin - A Syrrx and Takeda San Diego's DPP4 inhibitor being marketed under the brand name Nesina® to treat type 2 diabetes and the first drug to be discovered using structure-based design at Syrrx. He designed, built and implemented fragment-based crystallography drug discovery technology platforms at Syrrx, Merck and Metabasis. Dr. Prasad is the founder and Principal Consultant of Nnavata LLC. Prior to founding Nnavata, he was the Director and Head of Protein Science at Ventus Therapeutics, Waltham, MA, a clinical-stage biopharmaceutical company deploying leading-edge structural biology and unique computational chemistry tools to develop a robust pipeline of novel medicines in immunology, inflammation and neurology. He has co-authored over 40 peer-reviewed research articles and holds 6 US and international patents. He serves on the editorial board of Current Protein and Peptide Science, Chemical Sciences Journal and Organic and Medicinal Chemistry International Journal. Dr. Prasad obtained his PhD in Biophysics from the Indian Institute of Science, Bangalore, India and post-doctoral training at the University of Minnesota Medical School and the Scripps Research Institute, La Jolla, California, where he was Assistant Professor. Since 2024, he has served as a member of the board of directors of the Brain Cancer Research Institute. Dr. Prasad has raised millions in funding from NIH and the Michael J Fox Foundation for Parkinson’s research. He also serves on the editorial boards of Organic & Medicinal Chemistry International Journal and Chemical Sciences Journal, Omics Publications.
公司職務
- 公司名稱Drugs Made In America Acquisition Corp.股票代碼DMAA職務Independent Director關聯證券
- 公司名稱Drugs Made In America Acquisition II Corp.股票代碼DMII職務Independent Director關聯證券
